Real-world data on pain management and effectiveness of anti-tumour necrosis factor agents in refractory livedoid vasculopathy

被引：6
作者：
Gao, Y. [1 ]
Jin, H. [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Complex Severe & Rare Dis, Natl Clin Res Ctr Dermatol & Immunol Dis, Dept Dermatol,Peking Union Med Coll Hosp, Beijing, Peoples R China
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2022年 / 36卷 / 01期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1111/jdv.17613
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E46 / E48
页数：3
相关论文
共 8 条
  • [1] Livedoid Vasculopathy: Clinical Features and Treatment in 24 Chinese Patients
    Feng, Suying
    Su, Wei
    Jin, Peiying
    Shao, Changgeng
    [J]. ACTA DERMATO-VENEREOLOGICA, 2014, 94 (05) : 574 - 578
  • [2] Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: a retrospective analysis
    Gao, Yimeng
    Jin, Hongzhong
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (01) : 178 - 183
  • [3] Refractory ulcerations associated with livedoid vasculopathy successfully treated with tofacitinib
    Jia, Ertao
    Yan, Guangyao
    Xiao, Min
    Geng, Hongling
    Wei, Jiaxin
    Zhang, Jianyong
    [J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [4] Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction
    Kerk, Nina
    Goerge, Tobias
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 (05): : 407 - 411
  • [5] Livedoid vasculopathy in Koreans: clinical features and response to rivaroxaban treatment
    Lee, J. S.
    Cho, S.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (04) : E176 - E178
  • [6] Livedoid vasculopathy
    Provenza, Jose Roberto
    Pedri, Lucas Eduardo
    Provenza, Gabriel Mesquita
    [J]. REVISTA BRASILEIRA DE REUMATOLOGIA, 2016, 56 (06) : 554 - 556
  • [7] Vieira R, 2016, ACTA REUMATOL PORT, V41, P273
  • [8] Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial
    Weishaupt, Carsten
    Stroelin, Anke
    Kahle, Birgit
    Kreuter, Alexander
    Schneider, Stefan W.
    Gerss, Joachim
    Eveslage, Maria
    Drabik, Attyla
    Goerge, Tobias
    [J]. LANCET HAEMATOLOGY, 2016, 3 (02): : E72 - E79
1